AnaptysBio (NASDAQ:ANAB) Upgraded at Wolfe Research

Wolfe Research upgraded shares of AnaptysBio (NASDAQ:ANAB) to a strong-buy rating in a report released on Monday morning, MarketBeat Ratings reports.

Several other brokerages have also issued reports on ANAB. Truist Financial cut their price objective on AnaptysBio from $30.00 to $20.00 and set a “hold” rating for the company in a report on Wednesday, December 18th. BTIG Research downgraded AnaptysBio from a “buy” rating to a “neutral” rating in a research note on Monday, December 2nd. UBS Group boosted their price target on AnaptysBio from $23.00 to $33.00 and gave the company a “neutral” rating in a research note on Wednesday, October 30th. Wells Fargo & Company cut their price objective on shares of AnaptysBio from $56.00 to $40.00 and set an “overweight” rating on the stock in a research report on Thursday, December 12th. Finally, JPMorgan Chase & Co. decreased their target price on shares of AnaptysBio from $66.00 to $36.00 and set an “overweight” rating for the company in a research report on Thursday, December 19th. Four equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, AnaptysBio presently has a consensus rating of “Moderate Buy” and an average target price of $40.08.

AnaptysBio Price Performance

NASDAQ ANAB opened at $16.06 on Monday. The firm has a market capitalization of $488.71 million and a price-to-earnings ratio of -2.64. The company has a 50 day simple moving average of $17.05 and a 200-day simple moving average of $26.77. AnaptysBio has a 52-week low of $12.51 and a 52-week high of $41.31.

AnaptysBio (NASDAQ:ANAB) last released its earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.72) by $0.58. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. The company had revenue of $30.02 million during the quarter, compared to the consensus estimate of $7.92 million. On average, analysts predict that AnaptysBio will post -6.08 EPS for the current year.

Insider Buying and Selling

In other AnaptysBio news, Director Ecor1 Capital, Llc acquired 65,184 shares of the business’s stock in a transaction that occurred on Monday, December 30th. The stock was acquired at an average price of $12.92 per share, with a total value of $842,177.28. Following the transaction, the director now owns 7,860,180 shares of the company’s stock, valued at approximately $101,553,525.60. This trade represents a 0.84 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 33.70% of the stock is owned by insiders.

Institutional Trading of AnaptysBio

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. lifted its holdings in shares of AnaptysBio by 11.1% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,452 shares of the biotechnology company’s stock worth $85,000 after buying an additional 644 shares during the last quarter. Algert Global LLC increased its position in AnaptysBio by 11.8% during the second quarter. Algert Global LLC now owns 10,178 shares of the biotechnology company’s stock worth $255,000 after acquiring an additional 1,078 shares during the period. Rhumbline Advisers raised its stake in AnaptysBio by 3.8% during the 4th quarter. Rhumbline Advisers now owns 30,077 shares of the biotechnology company’s stock valued at $398,000 after purchasing an additional 1,111 shares during the last quarter. nVerses Capital LLC boosted its holdings in AnaptysBio by 700.0% in the 3rd quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock valued at $54,000 after purchasing an additional 1,400 shares during the period. Finally, Values First Advisors Inc. acquired a new stake in AnaptysBio in the 3rd quarter worth $49,000.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.